RESUMEN
Leptin is an adipocyte-derived hormone that regulates appetite and energy expenditure via the hypothalamus. Since the majority of obese subjects are leptin resistant, leptin sensitizers, rather than leptin itself, are expected to be anti-obesity drugs. Endoplasmic reticulum (ER) stress in the hypothalamus plays a key role in the pathogenesis of leptin resistance. ATP-deficient cells are vulnerable to ER stress and ATP treatment protects cells against ER stress. Thus, we investigated the therapeutic effects of oral 1,3-butanediol (BD) administration, which increases plasma ß-hydroxybutyrate and hypothalamic ATP concentrations, in diet induced obese (DIO) mice with leptin resistance. BD treatment effectively decreased food intake and body weight in DIO mice. In contrast, BD treatment had no effect in leptin deficient ob/ob mice. Co-administration experiment demonstrated that BD treatment sensitizes leptin action in both DIO and ob/ob mice. We also demonstrated that BD treatment attenuates ER stress and leptin resistance at the hypothalamus level. This is the first report to confirm the leptin sensitizing effect of BD treatment in leptin resistant DIO mice. The present study provides collateral evidence suggesting that the effect of BD treatment is mediated by the elevation of hypothalamic ATP concentration. Ketone bodies and hypothalamic ATP are the potential target for the treatment of obesity and its complications.
Asunto(s)
Peso Corporal/efectos de los fármacos , Butileno Glicoles/farmacología , Estrés del Retículo Endoplásmico/efectos de los fármacos , Hipotálamo/efectos de los fármacos , Leptina/farmacología , Obesidad/tratamiento farmacológico , Ácido 3-Hidroxibutírico/metabolismo , Adenosina Trifosfato/metabolismo , Animales , Butileno Glicoles/uso terapéutico , Metabolismo Energético/efectos de los fármacos , Hipotálamo/metabolismo , Masculino , Ratones , Ratones Obesos , Obesidad/metabolismoRESUMEN
Cachexia, a major cause of cancer-related death, is characterized by depletion of muscle and fat tissues, anorexia, asthenia, and hypoglycemia. Recent studies indicate that secretions of proinflammatory cytokines such as interleukin-6 (IL-6) play a crucial role in cachexia development, and that these cytokines are secreted from not only cancer cells but also host cells such as macrophages. In this study, we investigated the therapeutic effects of hochuekkito, a Kampo formula, on cachexia induced by colon 26 adenocarcinoma in mice. Hochuekkito treatment did not inhibit tumor growth, but significantly attenuated the reduction in carcass weight, food and water intake, weight of the gastrocnemius muscle and fat tissue around the testes, and decrease of serum triglyceride level compared with controls. Furthermore, hochuekkito treatment significantly reduced serum IL-6 level and IL-6 expression level in macrophages in tissues surrounding the tumor. In vitro studies showed that hochuekkito suppressed the production of IL-6 by THP-1 or RAW264.7 macrophage cells, although it did not affect IL-6 production by colon 26 carcinoma cells. These results suggest that hochuekkito inhibits the production of proinflammatory cytokines, particularly IL-6, by host cells such as macrophages. Therefore, hochuekkito may be a promising anticachectic agent for the treatment of patients with cancer.
RESUMEN
BACKGROUND: Cholinergic receptors are expressed in small cell lung cancer (SCLC); however, the distinct functions of muscarinic cholinergic receptor 3 (mAChR3) and the nicotinic cholinergic receptor (nAChR) in SCLC have not yet been completely elucidated. MATERIALS AND METHODS: RT-PCR and Western blotting were used to investigate the expression of cholinergic receptors. Flow cytometry was used to detect the integrin expression. Cell proliferation, adhesion and migration assays were carried out in vitro to determine the roles of the cholinergic receptors in SBC3 human SCLC cells. RESULTS: Both mAChR3 and nAChR were expressed in the SBC3 cells. Acetylcholine iodide (Ach) stimulated SBC3 cell proliferation, adhesion and migration toward fibronectin (Fn). The mAChR3 antagonist, 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP), or the nAChR antagonist, mecamylamine hydrochloride (Meca), inhibited SBC3 cell proliferation in the presence or the absence of exogenous Ach. 4-DAMP abrogated cell adhesion and migration toward Fn induced by Ach, while Meca had no effect. Interestingly, Ach did not alter Fn receptor (alphavbeta1 or alpha5beta1 integrin) expression, while anti-beta1 integrin antibody or anti-alphav and anti-alpha5 integrin antibody completely abrogated cell adhesion to Fn induced by Ach. CONCLUSION: Both mAChR3 and nAChR are expressed in SCLC. SBC3 cell proliferation is regulated in vitro through both cholinergic receptors. In contrast, SBC3 cell migration and adhesion toward Fn are modulated only by mAChR. Moreover, the stimulatory effects of Ach on cell adhesion and migration through mAChR3 are presumably modulated by functional alteration of alphavbeta1 and alpha5beta1 integrin, but not by any variation in their expression. The mAChR3 antagonist may therefore be a beneficial therapeutic modality for SCLC patients, especially those with chronic obstructive pulmonary disease (COPD) as a comorbidity.
Asunto(s)
Carcinoma de Células Pequeñas/metabolismo , Neoplasias Pulmonares/metabolismo , Receptor Muscarínico M3/fisiología , Receptores Nicotínicos/fisiología , Western Blotting , Carcinoma de Células Pequeñas/genética , Carcinoma de Células Pequeñas/patología , Adhesión Celular/fisiología , Línea Celular Tumoral , Movimiento Celular/fisiología , Agonistas Colinérgicos/farmacología , Medicamentos Herbarios Chinos/farmacología , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/patología , Antagonistas Muscarínicos/farmacología , Piperidinas/farmacología , Polisacáridos/farmacología , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Receptor Muscarínico M3/biosíntesis , Receptor Muscarínico M3/genética , Receptores Nicotínicos/biosíntesis , Receptores Nicotínicos/genética , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
Catechins in green tea have been shown to reduce a risk of coronary heart disease in epidemiological studies. Also, it has been reported catechins have hypolipidemic and antioxidant effects. Then, we investigated the effects of ground green tea drinking on the susceptibility of plasma and low-density lipoprotein (LDL) to the oxidation by CuSO4 ex vivo, and also evaluated daily food consumption using semiquantitative questionnaire. Five healthy female subjects consumed ground green tea (1.5 g/3 times/day) for 2 weeks after a washout period of 1 week, when they drank water instead of tea. After 2-week tea drinking, the subjects drank water again. They also filled food and drink-frequency questionnaires during 4 weeks to assess daily foods consumption to estimate the oxidizability of plasma and LDL. We measured the lag time of conjugated dienes formation of plasma and LDL to oxidation by CuSO4. The lag time of conjugated dienes formation are increased in all subjects after ground green tea consumption from 67+/-19 to 118+/-42 min in plasma and from 47+/-6 to 66+/-10 min in LDL. The cholesterol contents in plasma and LDL decreased 10 mg/dl after ground green tea consumption. The beta-carotene, alpha-tocopherol, vitamin C and uric acid contents in plasma did not change after ground green tea consumption. The superoxide dismutase (SOD) activity in plasma also remained unchanged during this study periods. These findings indicated that ground green tea consumption decreased susceptibility of plasma and LDL to oxidation and also modulated cholesterol metabolism and might prevent initiation and progression of atherosclerosis.